Ceryvyn Therapeutics Ltd
OPT
주식 순위
#31863
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
주가
$0.00846342
마지막 동기화: 2026-07-27
시가총액
$11.27M
변동 (1일)
0.00%
변동 (1년)
-99.75%
국가
AU
거래 Ceryvyn Therapeutics Ltd (OPT)
카테고리
Healthcare
Ceryvyn Therapeutics Ltd (OPT)의 수익
Jun 2025 기준 수익 TTM: $-169.06M
Ceryvyn Therapeutics Ltd의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-169.06M입니다. 2024년에 회사는 $-229.65M의 수익을 올렸으며 이는 2023년의 수익 $-220.69M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Ceryvyn Therapeutics Ltd의 수익 기록 (2000 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-169.06M | -1.22% |
| 2025 | $-171.16M | -25.47% |
| 2024 | $-229.65M | 4.06% |
| 2023 | $-220.69M | 61.47% |
| 2022 | $-136.68M | 102.76% |
| 2021 | $-67.41M | 300.56% |
| 2020 | $-16.83M | -32.59% |
| 2019 | $-24.96M | 16.56% |
| 2018 | $-21.42M | 197.14% |
| 2017 | $-7.21M | 19.44% |
| 2016 | $-6.03M | 25.84% |
| 2015 | $-4.80M | -21.15% |
| 2014 | $-6.08M | 11.14% |
| 2013 | $-5.47M | -28.41% |
| 2012 | $-7.64M | -39.60% |
| 2011 | $-12.66M | 157.11% |
| 2010 | $-4.92M | -23.67% |
| 2009 | $-6.45M | 529.14% |
| 2008 | $-1.03M | -111.84% |
| 2007 | $8.66M | -354.34% |
| 2006 | $-3.40M | -126.95% |
| 2005 | $12.63M | 348.18% |
| 2004 | $2.82M | -271.74% |
| 2003 | $-1.64M | -9.95% |
| 2002 | $-1.82M | 332.65% |
| 2001 | $-421.07K | -196.28% |
| 2000 | $437.36K | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -3,220.05% |
US
|
|
| $-3.09B | 1,725.93% |
US
|
|
| $-4.02B | 2,275.54% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,253.79% |
NL
|
